New insight into combatting drug-resistant prostate cancer: New research from the University of Eastern Finland sheds light on the significance of the glucocorticoid receptor in drug-resistant prostate cancer, showing that the development of drug resistance could be prevented by limiting the activity of coregulator proteins.
Glucocorticoids regulate vital biological processes by affecting gene encoding through a https://uefconnect.uef.fi/en/group/transcription-factor-crosstalk-in-cancers-paakinaho-lab/
Research articles:
Helminen L, Huttunen J, Tulonen M, Aaltonen N, Niskanen EA, Palvimo JJ, Paakinaho V. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer. Nucleic Acids Res. 2024 Jan 25;52(2):625-642. https://doi.org/10.1093/nar/gkad1126
Huttunen J, Aaltonen N, Helminen L, Rilla K, Paakinaho V. EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells. Cell Mol Life Sci. 2024 Apr 2;81(1):160. https://doi.org/10.1007/s00018-024-05209-z
https://news.cision.com/university-of-eastern-finland/r/new-insight-into-combatting-drug-resistant-prostate-cancer,c3959224
